Merck, Stallergenes Oral Allergy Immunotherapies Likely To Require Epi
Executive Summary
FDA Advisory committee is critical of how both companies defined anaphylaxis and reported safety events, but is OK with both novel treatments’ safety if co-packaged with epinephrine.